FDA Accepts Orexo’s Zubsolv for Review
Sweden’s Orexo has revealed that the US Food and Drug Administration (FDA) have accepted the New Drug Application (NDA) for their opioid dependence drug, Zubsolv, for review. Zubsolv is a sublingual formulation of Reckitt Benckiser’s Suboxone which governs a market that is predicted to reach sales of $1.5 billion in 2012 and continues to exhibit